title: Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.
abstract: Pseudomonas aeruginosa is a Gram-negative bacterium that causes serious lung infections in cystic fibrosis, non-cystic fibrosis bronchiectasis, immunocompromised, and mechanically ventilated patients. The arsenal of conventional antipseudomonal antibiotic drugs include the extended-spectrum penicillins, cephalosporins, carbapenems, monobactams, polymyxins, fluoroquinolones, and aminoglycosides but their toxicity and/or increasing antibiotic resistance are of particular concern. Improvement of existing therapies against Pseudomonas aeruginosa infections involves the use of liposomes - artificial phospholipid vesicles that are biocompatible, biodegradable, and nontoxic and able to entrap and carry hydrophilic, hydrophobic, and amphiphilic molecules to the site of action. The goal of developing liposomal antibiotic formulations is to improve their therapeutic efficacy by reducing drug toxicity and/or by enhancing the delivery and retention of antibiotics at the site of infection. The focus of this review is to appraise the current progress of the development and application of liposomal antibiotic delivery systems for the treatment pulmonary infections caused by P. aeruginosa.
authors.affiliation: Centre of Excellence for Gastrointestinal Inflammation & Immunity Research, Department of Pediatrics, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.
authors.forename: Misagh
authors.initials: M
authors.lastname: Alipour
authors.forename: Zacharias E
authors.initials: ZE
authors.lastname: Suntres
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry*; D002626:Chemistry, Pharmaceutical; D016503:Drug Delivery Systems; D024881:Drug Resistance, Bacterial; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008081:Liposomes; D008168:Lung / Q000187:drug effects* / Q000382:microbiology; D010743:Phospholipids / Q000737:chemistry*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000472:pathogenicity; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000900:Anti-Bacterial Agents; D008081:Liposomes; D010743:Phospholipids